Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. Nautilus Biotechnology is most often covered alongside Olink, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Nautilus Biotechnology, all published on February 27, 2026.
1 verified story tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Nautilus Biotechnology is most often covered alongside Olink, which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Nautilus Biotechnology, all published on February 27, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nautilus Biotechnology. Shared-story counts are live from our verified record — not editorial picks.
Seer (NASDAQ: SEER) reported quarterly earnings that exceeded analyst expectations by $0.03 per share, signaling resilience in the life sciences tools sector. The results highlight growing adoption of the company's Proteograph Product Suite as researchers increasingly prioritize high-resolution proteomics in drug discovery.
